Sanger sequencing and fragment analysis in less than one workday — from sample to answer

Celebrate Your Success with SeqStudio Flex

SeqStudio Flex 1st Anniversary bundle promotion and the landing page are live now!

To celebrate the progress and success of researchers working with the SeqStudio Flex Genetic Analyzer in the first year since launch, Thermo Fisher Scientific is providing a special promotion for customers to adopt SeqStudio Flex in a more cost-effective way.


The Applied Biosystems SeqStudio Flex Genetic Analyzer delivers the utmost in performance—ultimate flexibility, ease-of-use, connectivity, and remote serviceability. These features enable you to establish a rapid and accurate microbial identification process, while also achieving high sample throughput.
Download brochure ›
Take a 3D tour
Choose a service plan that’s right for you. Maximize system uptime, reduce repair costs and turnaround time, extend the life of your instrument, and help keep it running at peak performance with one of our comprehensive service plans. Choose from a variety of service options that balance your budget, productivity, uptime, and regulatory requirements. When it comes to superior services and support for your SeqStudio Flex Genetic Analyzer, we’ve got your back.
Download the services and support brochure

New MicroSEQ ID Microbial Identification Software v4.0 Launch

The Smart Deep Basecaller (SDB) is an innovative new basecalling algorithm that allows you to obtain improved Sanger sequencing output with reduced manual review time. Check it out!

Invivoscribe Announces IVDR Approval of the LeukoStrat® CDx FLT3 Mutation Assay for CE

We look forward to expanded customer usage of this fragment-analysis based assay that is approved for use on the 3500xL Dx genetic analyzer (IVDR-approved May 11, 2023, FDA-approved 2020).

The LeukoStrat CDx FLT3 Mutation Assay is a fragment analysis-based in vitro diagnostic test designed to detect internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from patients diagnosed with acute myelogenous leukemia (AML). FLT3 somatic variants are among the most common driver mutations as is one of the strongest predictors of overall survival in acute myeloid leukemia (AML), the deadliest form of leukemia.

You can read press release here.

Contact us for more product information and inquiries.